Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Seet
Raymond Chee-Seong
RC
Department of Medicine, Yong Loo Lin School of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. raymond_seet@nus.edu.sg
Chen
Christopher P L
CP
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications* / Q000503:physiopathology; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D000077144:Clopidogrel; D000075202:Contraindications; D006801:Humans; D000077405:Irbesartan; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D013777:Tetrazoles / Q000627:therapeutic use; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077405:Irbesartan; D013988:Ticlopidine; D001241:Aspirin